Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Marginal Zone Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is a single-arm, phase II study.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04416451
- Collaborators
- AbbVie
- Investigators
- Principal Investigator: Gottfried von Keudell, MD, PhD Memorial Sloan Kettering Cancer Center
Get Well Soon